AIM™ Technology: How it Works

Addressing Impaired Dendritic Cell Function: Natural antigen presenting cells (APC) play a critical role in the body’s immune system as they activate and direct other immune system cells, including T cells, in orchestrated attacks against specifically targeted antigens and cells. However, under certain disease conditions, natural APC such as Dendritic Cells can become impaired through damage, dysfunction or cell death. The AIM technology has been designed to drive specific immune system responses in a highly controllable and reproducible way independent of the functional effectiveness or abundance of the patient’s natural APC.

Artificial Antigen Presenting Cells: The AIM Technology is based on the pioneering work developing artificial Antigen Presenting Cells (aAPC) by NexImmune scientfic co-founders Mathias Oelke and Jonathan Schneck (Oelke and Schneck 2003 and 2010). These aAPC are engineered to mimic the core functions of natural Antigen Presenting Cells (eg. Dendritic Cells) by delivering two key antigen presenting cell signals: (i) an antigen-specific recognition signal delivered by an MHC molecule loaded with an antigenic peptide (Signal 1), and (ii) a co-stimulatory signal to direct action by the T cells (Signal 2).

aAPC Directly Engage and Activate T Cell Function: Following antigen-specific activation by either an aAPC or a natural antigen presenting cell, T cells undergo clonal selection and become either memory cells or cytotoxic effector cells. Effector cells are activated and perform cytotoxic killing of T cells in part through the release of cytotoxic granules. NexImmune’s proprietary aAPC engage directly with targeted T cell receptors (TCR) on endogenous naïve and memory T cells and are designed to stimulate a robust effector response with the generation of immunologic memory. This provides for both an immediate therapeutic response and sustainable activity by the stimulated cells.

Applications

The AIM technology has broad potential for future applications in cancer, autoimmune disease and infectious disease.

View Applications

Differentiation

AIM aAPC are able to precisely stimulate un-paralleled levels of antigen-specific T cells for treating disease.

View Differentiation

Patents & Publications

Foundational papers and intellectual property covering AIM technology.


View Publications